

- **Name:** Miso Kim
  - **Current Position & Affiliation:** Assistant Professor, Seoul National University Hospital
  - **Country:** Korea
- 

- **Educational Background:**

2009 M.D. / Seoul National University, Seoul, Korea  
2014 M.S. / College of Medicine, Seoul National University, Seoul, Korea  
Currently in the doctor's course, College of Medicine, Seoul National University, Seoul, Korea

- **Professional Experience:**

2009-2010 Internship, Seoul National University Hospital  
2010-2014 Residency, Internal Medicine, Seoul National University Hospital  
2014-2015 Clinical Fellow, Division of Hematology and Medical Oncology, Department of Internal Medicine, Seoul National University Hospital  
2015-2016 Clinical Instructor, Division of Hematology and Medical Oncology, Department of Internal Medicine, Seoul National University Hospital  
2016.3-Current Assistant Professor, Division of Hematology and Medical Oncology, Department of Internal Medicine, Seoul National University Hospital

- **Professional Organizations:**

Korean Medical Association  
Korean Association of Internal Medicine  
Korean Society of Medical Oncology  
Korean Cancer Association  
Korean Association for Lung Cancer  
European Society for Medical Oncology  
American Society of Clinical Oncology

- **Main Scientific Publications:**

Park C, **Kim M**, Kim MJ, Kim H, Ock CY, Keam B et al. Clinical application of next-generation sequencing-based panel to BRAF wild-type advanced melanoma identifies key oncogenic alterations and therapeutic strategies. *Molecular Cancer Therapeutics*. 2019 (Co-correspondence)

**Kim M**, Kim TM, Keam B, Kim YJ, Paeng JC, Moon KC, et al. A Phase II Trial of Pazopanib in Patients with Metastatic Alveolar Soft Part Sarcoma. *The oncologist*. 2018.

Yoo SH, **Kim M**, Yun YH, Keam B, Kim YA, Kim YJ, et al. Attitudes toward early

palliative care in cancer patients and caregivers: a Korean nationwide survey. *Cancer medicine*. 2018 (Co-first author)

**Kim M**, Keam B, Kim TM, Kim HG, Kim JS, Lee SS, et al. Phase II Study of Irinotecan and Cisplatin Combination Chemotherapy in Metastatic, Unresectable Esophageal Cancer. *Cancer research and treatment*. 2017

**Kim M**, Ku JH, Kwak C, Kim HH, Lee E, Keam B, et al. Predictive and Prognostic Value of Ribonucleotide Reductase Regulatory Subunit M1 and Excision Repair Cross-Complementation Group 1 in Advanced Urothelial Carcinoma (UC) Treated with First-Line Gemcitabine Plus Platinum Combination Chemotherapy. *PloS one*. 2015

**Kim M**, Kim TM, Kim KH, Keam B, Lee SH, Kim DW, et al. Ifosfamide, methotrexate, etoposide, and prednisolone (IMEP) plus L-asparaginase as a first-line therapy improves outcomes in stage III/IV NK/T cell-lymphoma, nasal type (NTCL). *Annals of hematology*. 2015